{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:34:17Z","timestamp":1790724857316,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.esmorw.2025.100121","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T15:52:51Z","timestamp":1742226771000},"page":"100121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Health care policies, drug costs, and time toxicities in biologics for HER2-positive breast cancer: cost minimization analysis of direct and indirect costs"],"prefix":"10.1016","volume":"8","author":[{"given":"J.L.","family":"Low","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.J.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmorw.2025.100121_bib1","series-title":"Great Policy Successes","first-page":"42","article-title":"The remarkable healthcare performance in Singapore","author":"Ramesh","year":"2019"},{"issue":"7","key":"10.1016\/j.esmorw.2025.100121_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2014.08.429","article-title":"Drug access through sharing public and individual responsibilities in the Public Health Care System of Singapore","volume":"14","author":"Tan","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.esmorw.2025.100121_bib4","series-title":"Why S\u2019pore Spends So Much on Cancer Treatment and How MediShield Life Changes Aim to Tackle This","author":"Lai","year":"2021"},{"key":"10.1016\/j.esmorw.2025.100121_bib5","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(21)00252-X","article-title":"Singapore\u2019s health-care system: key features, challenges, and shifts","volume":"398","author":"Tan","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.esmorw.2025.100121_bib6","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study","volume":"5","author":"Global Burden of Disease Cancer Collaboration","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmorw.2025.100121_bib7","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1200\/EDBK_159167","article-title":"Emerging therapeutic options for HER2-positive breast cancer","volume":"35","author":"Martin","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.esmorw.2025.100121_bib8","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1200\/JCO.2018.79.2697","article-title":"Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO Clinical Practice Guideline Update","volume":"36","author":"Giordano","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmorw.2025.100121_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100121_bib10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmorw.2025.100121_bib11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.esmorw.2025.100121_bib12","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.20.01204","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years\u2019 follow-up","volume":"39","author":"Piccart","year":"2021","journal-title":"J. Clin Oncol"},{"key":"10.1016\/j.esmorw.2025.100121_bib13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmorw.2025.100121_bib14","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmorw.2025.100121_bib15","article-title":"Real-world time trends in overall survival, treatments and patient characteristics in HR+\/HER2\u2212 metastatic breast cancer: an observational study of the SONABRE Registry","volume":"26","author":"Meegdes","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.esmorw.2025.100121_bib16","article-title":"Trends in anti-HER2 drugs consumption and influencing factors","volume":"10","author":"Liu","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.esmorw.2025.100121_bib17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41416-019-0480-z","article-title":"The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars","volume":"121","author":"Barbier","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmorw.2025.100121_bib18","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1177\/1078155221999712","article-title":"Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: a multidisciplinary approach","volume":"27","author":"DuMond","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.esmorw.2025.100121_bib19","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.pec.2020.08.013","article-title":"Cancer patients\u2019 perspectives on financial burden in a universal healthcare system: analysis of qualitative data from participants from 20 provincial cancer centers in Canada","volume":"104","author":"Fitch","year":"2021","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.esmorw.2025.100121_bib20","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1200\/JCO.19.03141","article-title":"Clinical cancer advances 2020: annual report on progress against cancer from the American Society of Clinical Oncology","volume":"38","author":"Markham","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmorw.2025.100121_bib21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejca.2021.03.047","article-title":"Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study","volume":"152","author":"O\u2019Shaughnessy","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmorw.2025.100121_bib22","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","article-title":"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial","volume":"13","author":"Ismael","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmorw.2025.100121_bib23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2016.03.087","article-title":"HannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up","volume":"62","author":"Jackisch","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmorw.2025.100121_bib24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejca.2017.05.010","article-title":"Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study\u2019s primary analysis of 2573 patients","volume":"82","author":"Gligorov","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmorw.2025.100121_bib25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejca.2017.08.019","article-title":"Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: final analysis of the randomised, two-cohort PrefHer study","volume":"86","author":"Pivot","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmorw.2025.100121_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.0339","article-title":"Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH phase 3 randomized clinical trial","volume":"5","author":"Jackisch","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmorw.2025.100121_bib27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(20)30536-2","article-title":"Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study","volume":"22","author":"Tan","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmorw.2025.100121_bib28","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/annonc\/mdu364","article-title":"Patients\u2019 preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study","volume":"25","author":"Pivot","year":"2014","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmorw.2025.100121_bib29","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","article-title":"Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmorw.2025.100121_bib30","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12325-021-01996-0","article-title":"White paper on the value of time savings for patients and healthcare providers of breast cancer therapy: the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection as an example","volume":"39","author":"Jackisch","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.esmorw.2025.100121_bib31","series-title":"NCIS to Bring More Cancer Treatments Closer to Patients by Adding Satellite Clinics","author":"Tan","year":"2024"},{"key":"10.1016\/j.esmorw.2025.100121_bib32","series-title":"The Use of Cost Minimisation Analysis for the Appraisal of Health Technologies. Report by the Nice Decision Support Unit","author":"Wailoo","year":"2019"},{"key":"10.1016\/j.esmorw.2025.100121_bib33","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/1471-2458-12-439","article-title":"The weight of nations: an estimation of adult human biomass","volume":"12","author":"Walpole","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.esmorw.2025.100121_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jcpo.2017.05.001","article-title":"Cost minimization analysis of Herceptin subcutaneous versus Herceptin intravenous treatment for patients with HER2+ Breast cancer in Greece","volume":"13","author":"Mylonas","year":"2017","journal-title":"J Cancer Policy"},{"key":"10.1016\/j.esmorw.2025.100121_bib35","series-title":"Why a Housewife\u2019s Contributions Can Be Worth Millions in Singapore","author":"Boon","year":"2021"},{"key":"10.1016\/j.esmorw.2025.100121_bib36","author":"Dayani"},{"key":"10.1016\/j.esmorw.2025.100121_bib38","series-title":"Highlights of Prescribing Information","year":"2015"},{"key":"10.1016\/j.esmorw.2025.100121_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103633","article-title":"An innovative model of delivering cancer care in the community: the experience of a tertiary cancer centre in Singapore","volume":"9","author":"Wong","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmorw.2025.100121_bib41","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4236\/abcr.2013.24022","article-title":"Subcutaneous trastuzumab (Herceptin\u00ae): a UK time and motion study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancer","volume":"2","author":"Burcombe","year":"2013","journal-title":"Adv Breast Cancer Res"},{"key":"10.1016\/j.esmorw.2025.100121_bib42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejogrb.2017.12.006","article-title":"Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: a time, motion and cost assessment study in a lean operating day care oncology unit","volume":"221","author":"Tjalma","year":"2018","journal-title":"Eur J Obst Gynecol Reprod Biol"},{"key":"10.1016\/j.esmorw.2025.100121_bib43","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41416-020-01255-z","article-title":"Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice","volume":"124","author":"Waller","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmorw.2025.100121_bib44","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.21.02810","article-title":"The time toxicity of cancer treatment","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmorw.2025.100121_bib45","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamaoto.2014.1570","article-title":"Unintended consequences of expensive cancer therapeutics \u2013 the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley lecture","volume":"140","author":"Fojo","year":"2014","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.esmorw.2025.100121_bib46","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1001\/jamaoncol.2021.3600","article-title":"Has the current oncology value paradigm forgotten patients\u2019 time?: Too little of a good thing","volume":"7","author":"Fundytus","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmorw.2025.100121_bib47","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/OP.20.01071","article-title":"Maximizing home time for persons with cancer","volume":"17","author":"Banerjee","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.esmorw.2025.100121_bib48","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/OP.21.00662","article-title":"Time-related burdens of cancer care","volume":"18","author":"Gupta","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.esmorw.2025.100121_bib49","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1200\/JCO.2020.39.28_suppl.73","article-title":"Evaluation of real-world cost savings and utilization of biosimilar drugs in a community-based oncology practice","volume":"39","author":"Sanyal","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmorw.2025.100121_bib50","first-page":"3","article-title":"Biosimilar cost savings in the United States: initial experience and future potential","volume":"7","author":"Mulcahy","year":"2018","journal-title":"Rand Health Q"},{"key":"10.1016\/j.esmorw.2025.100121_bib51","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3390\/ph7090943","article-title":"Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: a physician survey in the United States and emerging markets","volume":"7","author":"Lammers","year":"2014","journal-title":"Pharmaceuticals"},{"issue":"2-3","key":"10.1016\/j.esmorw.2025.100121_bib52","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.healthpol.2013.11.006","article-title":"Access to innovation: is there a difference in the use of expensive anticancer drugs between French hospitals?","volume":"116","author":"Bonastre","year":"2014","journal-title":"Health Policy"},{"key":"10.1016\/j.esmorw.2025.100121_bib53","series-title":"Evaluating the Site of Service and Oncology Care Costs","year":"2024"},{"key":"10.1016\/j.esmorw.2025.100121_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100625","article-title":"Cost-effectiveness of cancer drugs: comparative analysis of the United States and England","volume":"29-30","author":"Cherla","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"suppl 13","key":"10.1016\/j.esmorw.2025.100121_bib56","article-title":"Abstract CT143: pembrolizumab bioavailability after subcutaneous administration: analysis from the KEYNOTE-555 Cohort A in metastatic melanoma","volume":"81","author":"Jacobs","year":"2021","journal-title":"Cancer Res"},{"issue":"30","key":"10.1016\/j.esmorw.2025.100121_bib57","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.24.01001","article-title":"Subcutaneous versus Intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the phase 3 PALOMA-3 study","volume":"42","author":"Leighl","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmorw.2025.100121_bib58","doi-asserted-by":"crossref","first-page":"9126","DOI":"10.1200\/JCO.2023.41.16_suppl.9126","article-title":"Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: the PALOMA study\u2014updated safety and identification of the recommended phase 2 dose","volume":"41","author":"Minchom","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820125000104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820125000104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:17:01Z","timestamp":1750983421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820125000104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":54,"alternative-id":["S2949820125000104"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100121","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health care policies, drug costs, and time toxicities in biologics for HER2-positive breast cancer: cost minimization analysis of direct and indirect costs","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100121"}}